EMA accepts Eisai's marketing authorization application for lecanemab to treat early Alzheimer's disease
BioArctic AB’s (publ) partner Eisai announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (brand name in the US: Leqembi), an investigational anti-amyloid beta (Aß) protofibril antibody, …